Tamura S, Fujikura M, Takahashi S, Maebo A, Nakano T, Yamada W, Fujii J, Nabeshima K, Hada T, Higashino K
Gan To Kagaku Ryoho. 1985 Dec;12(12):2338-44.
To investigate whether lithium carbonate ameliorates the leukopenia and infectious complication that accompany systemic chemotherapy, we studied 19 patients with small cell carcinoma of the lung receiving combination chemotherapy. Eight patients received systemic chemotherapy and lithium carbonate and 11 patients received systemic chemotherapy alone. The mean leukocyte count nadir during chemotherapy was significantly higher in the patients of the lithium group than in the patients of the control group (p less than 0.05). Percentage of infectious complication related to leukopenia was lower in the lithium group than in the control group, although there was no significant difference between these two groups. There was almost no significant side effect except for liver dysfunction in one patient. We therefore believe that lithium carbonate is an effective and safe drug against leukopenia during cytotoxic chemotherapy.
为研究碳酸锂是否能改善全身化疗所伴随的白细胞减少及感染并发症，我们对19例接受联合化疗的小细胞肺癌患者进行了研究。8例患者接受全身化疗加碳酸锂，11例患者仅接受全身化疗。碳酸锂组患者化疗期间白细胞计数最低点均值显著高于对照组患者（p<0.05）。尽管两组之间无显著差异，但碳酸锂组与白细胞减少相关的感染并发症百分比低于对照组。除1例患者出现肝功能障碍外，几乎没有明显的副作用。因此，我们认为碳酸锂是一种在细胞毒性化疗期间对抗白细胞减少的有效且安全的药物。
